Neuroinflammation Clinical Strategies and Treatment Applications

What Is Neuroinflammation?

Neuroinflammation is chronic activation of the brain's glial cells, the immune cells that make up roughly 90 percent of brain tissue, triggered by traumatic brain injury, infection, chronic intestinal permeability, or sustained physiological stress.

Why Does Neuroinflammation Get Missed When Labs and Imaging Look Normal?

Every practitioner has seen this patient. Two years of brain fog and depression that three antidepressants did not touch. Bloodwork unremarkable, an MRI read as normal for age, and a long history of being told nothing is physically wrong. Nine years earlier there was a concussion, treated as resolved in a few weeks.

It was not resolved. It was primed.

Neuroinflammation rarely announces itself as inflammation, which is exactly why it gets missed. The brain has no pain receptors, so it does not hurt. It loses function instead: slowed processing, mood that does not track with life, fatigue out of proportion to effort. A clinician scanning for the usual signs of inflammation will not find them here.

Recognizing the pattern as glial priming changes the workup. History moves ahead of labs, and a normal MRI stops being a reason to rule it out.

How glial cells become primed

Glial cells, principally microglia and astrocytes, are the brain's resident immune system: they clear debris, prune synaptic connections, and regulate the blood-brain barrier. Under normal conditions, they shift between a resting state and a temporarily activated state in response to injury or infection, then return to baseline once the threat resolves.

Chronic or repeated insult changes that pattern permanently. Once glial cells become primed, they do not return to a true resting state. A subsequent trigger, an infection, a poor night of sleep, a single alcoholic drink, produces an inflammatory response disproportionate to the trigger itself.

This is the mechanism behind a pattern most practitioners have seen without naming it: the patient who reports being "never the same" after an injury or illness that should have been minor.

Three pathways into the brain

Neuroinflammation reaches the brain through three distinct mechanisms, and distinguishing between them shapes the clinical approach.

The first is direct neuron injury: traumatic brain injury, stroke, or infection that damages brain tissue directly.

The second is breakdown of the blood-brain barrier, which allows circulating inflammatory mediators and, in some cases, autoantibodies to cross into brain tissue that is normally protected from them.

The third is peripheral activation that traverses the barrier without breaching it: cytokines such as TNF-alpha, IL-1β, and IL-6, generated by intestinal permeability, systemic autoimmunity, or chronic infection elsewhere in the body, cross an intact barrier and directly activate microglia and astroglia.

That third pathway is the one most consistently missed in practice because it does not require a head injury or a positive MRI finding. A patient with long-standing intestinal permeability or an autoimmune condition can develop meaningful neuroinflammation with no history of trauma at all.

Why standard labs and imaging often miss neuroinflammation

No single lab test diagnoses neuroinflammation. That is the operational reality practitioners have to work around, not a gap in available technology. Labs and imaging confirm contributing mechanisms, not the presence of neuroinflammation itself, which means the diagnosis is built from clinical history and exam findings first.

Markers worth tracking in the right context include S100-B for blood-brain barrier integrity, high-sensitivity CRP, and intestinal permeability markers, alongside a detailed history that prioritizes head injury, infection, and vascular events over the gut-first assumption many practitioners default to.

Differentiating transient, chronic, and primed presentations

Not every case of neuroinflammation carries the same clinical weight, and treating them all identically is where outcomes tend to fall short. A useful working distinction separates transient inflammation, a temporary response that resolves with standard anti-inflammatory support, from chronic inflammation that persists without resolving, and from true glial priming, in which the sensitized response has become fixed.

A fourth category, neurological autoimmunity, requires its own antibody and exam-based confirmation and does not resolve through diet and lifestyle intervention alone.

History is the fastest way to sort a patient into one of these categories. A single recent stressor with no prior injury history points toward transient. A pattern of flares following disproportionately small triggers points toward priming. Getting this distinction right changes what a reasonable course of care looks like and how quickly a practitioner should expect to see movement.

Where this shows up in practice

Neuroinflammation is not a standalone diagnosis so much as a mechanism underneath several presentations practitioners already see regularly.

In treatment-resistant depression, inflammatory cytokines suppress tryptophan conversion toward serotonin and redirect it through the kynurenine pathway, producing a mood disorder that does not respond to neurotransmitter support alone.

In cognitive decline and dementia, blood-brain barrier breakdown has been shown in some patients to precede amyloid deposition, positioning it as a contributing mechanism rather than a downstream consequence. In children, over-activated glial cells are diverted from their developmental role in synaptic pruning, with implications for attention and processing.

Building a clinical approach

The Neuroinflammation course walks through this sequence in full: the assessment sequence, the mechanisms linking glial priming to specific presentations, and the clinical decision-making for cases that have already undergone standard workups without an answer.

The Kharrazian Institute has created in-depth clinical assessment materials on the following topics: neuroinflammation assessment strategies for practitioners; the blood-brain barrier's role in dementia; clinical assessment of neuroinflammatory depression; and a functional medicine approach to mood disorders beyond serotonin.